Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Canagliflozin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Janssen Scientific Affairs
Deal Size : Not Applicable
Deal Type : Not Applicable
Heart Failure Symptoms Improved with A Type 2 Diabetes Medicine in Fully Remote Trial
Details : Adults with heart failure who took canagliflozin, a medication originally developed to treat type 2 diabetes, reported improvements in their heart failure symptoms whether or not they also had type 2 diabetes.
Brand Name : JNJ-28431754
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 14, 2021
Lead Product(s) : Canagliflozin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Janssen Scientific Affairs
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?